The disclosure relates to in vivo andex vivouses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.
本公开涉及使用二氢烟酰胺核苷酸(NRH)、二氢
烟酸核苷酸(NARH)及其还原衍
生物的体内和体外应用,用于治疗免疫相关疾病(例如全身性炎症反应综合征和脓毒症)、肾脏疾病(例如急性肾损伤和肝肾综合征[HRS])、肝脏疾病(例如急性肝衰竭和HRS)、溶血性疾病(例如溶血和溶血性贫血)以及与氧化应激、损伤或损伤相关的疾病和状况(例如高
铁血红蛋白血症和贫血)。 NRH、NARH及其还原衍
生物可以单独或与一个或多个其他治疗剂(例如抗炎剂或/和
抗氧化剂)联合使用,进行体内或体外治疗。